Date and Time: 13th September 2012, 9:30 – 16:00

Minutes: Confirmed

Guideline Development Group Meeting 4
Place: Boardroom, NCGC, 180 Great Portland Street, London, W1W 5QZ

GDG Present: Fiona Lecky (Chair) (FL) (Present for notes 1 – 8)
Mukul Agarwal (MA) (Present for notes 1 – 8)
Robin Clarke (RC) (Present for notes 1 – 8)
Barbara Green (BG) (Present for notes 1 – 8)
Kieran Hogarth (KH) (Present for notes 1 – 8)
Peter Hutchinson (PH) (Present for notes 1 – 8)
Mark Lyttle (ML) (Present for notes 1 – 8)
David Menon (DM) (Present for notes 1 – 8)
Lisa Turan (LT) (Present for notes 3 – 8)

NCGC Present: Sarah Hodgkinson (SH) (Present for notes 1 – 8)
Sue Latchem (SL) (Present for notes 1 – 8)
Antonia Morga (AM) (Present for notes 1 – 8)
Carlos Sharpin (CS) (Present for notes 1 – 8)

In attendance:

NICE Staff: Sarah Dunsdon (SD) (Present for notes 4 – 8)

Observers: None

Agenda item

1. Welcome introductions and apologies
FL welcomed the group to the fourth meeting of this GDG. The GDG accepted the NICE minutes and working notes as an accurate record of the previous meeting and no changes were made.

FL asked each member to state any changes to their declarations of interest. David Menon noted that he had been contacted by AstraZeneca regarding his opinion on a new neuroprotective agent and will meet with them in the next few weeks. The GDG and NCGC technical team declared no changes.

The GDG acknowledged apologies from Gaby Lomas and Paul Wallman.

2. Introduction to making recommendations and linking evidence
CS presented an introduction to making recommendations. He also talked through a worked example of a linking evidence to recommendation (LETR) section which details how the GDG reached their recommendation.

3. Selection of patient with head injury for imaging – who are on anticoagulant and anti-platelet therapy.
CS presented the findings for the anticoagulant/antiplatelet review. CS discussed the
Agenda item

finding of the review for patients taking anti-platelet agents.

AM discussed the limited cost effectiveness evidence in this area. The GDG discussed the variation in diagnosis and management for coagulated patients.

SH gave an update of the discussion from the previous GDG and the agreed action points. She detailed the quality assessment conducted and updates from the previous meeting. The GDG discussed the evidence presented, including evidence from the anticoagulant question.

SH gave an update of the discussion from the previous GDG and the agreed action points. She detailed the quality assessment and updates from the previous meeting. The GDG discussed the evidence presented and their next steps.

6. Selection of patients with head injury for imaging – using diagnostic circulating biomarkers
SH presented an introduction to making research recommendations and summarized the work so far on drafting a research recommendation on biomarkers.

7. Update and queries on clinical prediction rules for cervical spine imaging
AM discussed the economic plan and the model for cervical spine injury. She outlined initial queries regarding prevalence, management, diagnosis and patient pathways.

8 Summary of next steps and any other business
SH urged the GDG to use Claromentis both for reading through documents prior to attending meetings and also for checking out documents and commenting/adding introduction and LETRs.

Date, time and venue of the next meeting

Tuesday 30th October 2012, 9.30 – 16.00 Boardroom, NCGC, 180 Great Portland Street, London, W1W 5QZ.